First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialDaily Markets (press release)ROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis … …read more &nbs… Continue reading
Migration capacity of human umbilical cord mesenchymal stem cells towards …Science CodexGlioblastoma is the most common ma-lignant primary brain tumor in adults. The aggressive growth manner, characterized by marked angiogenesis and extensive tumor cell invasion into normal brain parenchyma with frequent formation of tumor … …read more &nbs… Continue reading
Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell TrialNASDAQ(RTTNews.com) – Neuralstem Inc. ( CUR ) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at Emory …First Patient Treated In … Continue reading
Neuralstem: First Patient Treated In Phase II Of ALS Stem Cell TrialRTT NewsNeuralstem Inc. (CUR: Quote) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) at Emory University … and more …read more &nbs… Continue reading
BioNews TexasDaniel Lodge, Ph.D., senior author and assistant professor of pharmacology in the School of Medicine, believes that these interneurons can be replaced with stem cells and that should restore lost function. In the current study, Lodge and colleagues … and more …read more &nbs… Continue reading
Scientists Warn to Avoid Treatment by Fake & Untested Stem CellFrench TribuneMedical experts are concerned that people are buying untested stem cells for medical treatment, which could prove to be very dangerous. Most of the people buying these phony stem cells are suffering from incurable degenerative diseases, who are ready … …read more &nbs… Continue reading
First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialWall Street JournalROCKVILLE, Md., Sept. 10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis … …read more &nbs… Continue reading
First Patient Treated In Phase II Of Neuralstem ALS Stem Cell TrialPR Newswire (press release)10, 2013 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the first patient was treated in its Phase II trial using NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s … and … Continue reading